Abstract | Disorders of sex development (DSDs) are a diverse group of conditions that can be challenging to diagnose accurately using standard phenotypic and biochemical approaches. Obtaining a specific diagnosis can be important for identifying potentially life-threatening associated disorders, as well as providing information to guide parents in deciding on the most appropriate management for their child. Within the past 5 years, advances in molecular methodologies have helped to identify several novel causes of DSDs; molecular tests to aid diagnosis and genetic counselling have now been adopted into clinical practice. Occasionally, genetic profiling of embryos prior to implantation as an adjunct to assisted reproduction, prenatal diagnosis of atrisk pregnancies and confirmatory testing of positive results found during newborn biochemical screening are performed. Of the available genetic tests, the candidate gene approach is the most popular. New highthroughput DNA analysis could enable a genetic diagnosis to be made when the aetiology is unknown or many differential diagnoses are possible. Nonetheless, concerns exist about the use of genetic tests. For instance, a diagnosis is not always possible even using new molecular approaches (which can be worrying for the parents) and incidental information obtained during the test might cause anxiety. Careful selection of the genetic test indicated for each condition remains important for good clinical practice. The purpose of this Review is to describe advances in molecular biological techniques for diagnosing DSDs.
Introduction
Mammalian sex development is a complex process that depends on three general steps. The first step is establishment of the chromosomal complement at fertilization so that the typical male fetus has one X chromosome and one Y chromosome and the typical female fetus has two X chromosomes (sometimes referred to as 'chromosomal sex').
The second step is gonad determination ('sex determination'). During this process, the bipotential gonad develops into either a testis or an ovary ('gonadal sex'). The presence of the SRY gene on the Y chromosome is usually sufficient to promote testis development, whereas an ovary will typically develop in the absence of SRY expression. 1 The final step is differentiation of the internal and external genitalia ('sex differentiation'). This process occurs under the influence of hormones secreted by the gonad and results in the 'phenotypic sex' . All embryos have both para mesonephric ducts (Müllerian ducts) and mesonephric ducts (Wolffian ducts) early in gestation. If a testis develops, anti-Müllerian hormone (a glyco protein secreted from the Sertoli cells), acts on its receptor in the Müllerian ducts, which causes the Müllerian ducts to regress. Testosterone secreted by the testicular Leydig cells acts on androgen receptors in the Wolffian ducts to induce the development of the epididymis, deferent ducts and seminal vesicles. Testosterone is also reduced to dihydrotestosterone, which acts on androgen receptors to cause androgenization (masculinization) of the external genitalia. The female reproductive tract (uterus and upper vagina) develops even in the absence of any gonad; however, ovarian development and its ma intenance are now known to be active processes. 1 Mutations or alterations in the genes that regulate gonad determination and sex differentiation can lead to dis orders of sex development (DSDs). The Chicago Consensus splits DSDs into three broad categories: sex chromosome DSDs; 46,XY DSDs; and 46,XX DSDs. 2 The karyotype per se does not make a child 'male' or 'female' and a specific diagnosis should ideally be reached for each individual. However, the ability to rapidly detect X chromosomes and Y chromosomes using techniques such as fluorescent in situ hybridiza tion (FISH) means that a broad diagnostic category can be reached in around 48 h; counselling and bio chemical and genetic investigations can then be focused accordingly.
Sex chromosome DSDs result from differences in the number of sex chromosomes. Sex chromosome DSDs include the sex chromosome aneuploidies such as Turner syndrome (45,X) and Klinefelter syndrome (47, XXY) ; however, these children do not present with genital differences in early life in most situations. In contrast, children with 45,X/46,XY mosaicism often present with atypical genitalia in the newborn period.
structures. 46 ,XY DSDs can result from impaired production of testosterone, decreased conversion of testosterone to dihydrotestosterone or impaired peripheral action of these hormones. 4 Depending on the underlying condition, testicular tissue can be absent, partially or completely dy sgenetic, or even seem normal upon histological analysis. 5, 6 46,XX DSDs result from fetal exposure to high levels of androgens and are characterized by ambiguous or 'male' external genitalia. These DSDs are most often caused by congenital adrenal hyperplasia (CAH). Patients with 46,XX DSDs usually have ovaries and Müllerian structures; however, a rare subgroup of patients have isolated testicular tissue (46,XX testicular DSD) or both testicular and ovarian tissue (46,XX ovotesticular DSD). 7 Although DSDs can present at many different ages, one of the most common presentations is with ambiguous (or atypical) genitalia at birth. Sex assignment can be a complex process and is especially challenging for babies with a 46,XY karyotype, poorly developed genitalia and gonads that are not palpable. 8 Meticulous assessment and counselling by a multidisciplinary team is essential in the sex assignment process. Reaching a specific diagnosis can be important for assessing the risk of developing harmful conditions associated with DSDs (such as renal or adrenal disorders), and to some extent for predicting the long-term outcomes such as gender identity, endocrine function, potential fertility and risk of gonadal tumours. The rapid identification of a molecular cause can sometimes be very helpful in decision-making. 9 This Review analyses the contribution of molecular biology techniques to the diagnosis and management of DSDs, as well as discussing advances in these techniques.
Molecular approaches to diagnosis
Candidate gene sequencing Historically, candidate genes for DSDs have been identified following analysis of deleted or duplicated chromosomal regions (copy number variations [CNVs] ) that are associated with DSDs phenotypes; 10 linkage analysis, animal models and biochemical profiles that suggest blockade of a key enzyme or protein in a biochemical pathway have also been used. Following the identification of a gene that could cause a DSD, conventional Sanger sequencing has typically been used to analyse groups of patients categorized by their phenotype and hormonal profiles. Nowadays, Sanger sequencing is still the main methodological tool used to investigate inherited mutations. 11 When clear biochemical evidence suggests a specific pathway is disrupted, the chances of identifying a change in the relevant gene are generally high (for example, in CYP17A1 and HSD17B3). 12, 13 However, where the potential cause of the DSD is not clear or specifically indicated by the hormonal profile (such as testicular dysgenesis), the candidate gene approach provides a molecul ar diagnosis in only ~20% of cases. 2 
Copy number variations
In addition to candidate gene sequencing, specific CNVs can be analysed using techniques such as FISH, quantitative PCR and multiplex ligation-dependent probe amplification. In a small number of cases, duplication or deletion of genes or specific exons can be identified. For example, in 46,XY gonadal dysgenesis, SRY is deleted in ~5% of patients and the region of Xp21 that contains NR0B1 is duplicated in ~5% of patients. 14 
Array-comparative genomic hybridization
In the past 5 years, high-throughput molecular tools have enabled simultaneous analyses of CNV or parallel sequencing of many genes with much greater efficiency than was previously possible. 15 Among these genetic tests, array-comparative genomic hybridization (array-CGH), single nucleotide polymorphism (SNP) genotyping array, whole-exome sequencing or whole-genome sequencing can enable a genetic diagnosis to be made when a differential diagnosis is likely, biochemical tests are unclear or even in the absence of prior clinical suspicion. [16] [17] [18] Array-CGH enables rapid screening to identify submicroscopic genomic imbalances, which results in the identification of known and potentially causative CNVs on a genome-wide scale. Array-CGH is a powerful highresolution technique with the potential to detect small genomic changes. This diagnostic tool is starting to be used routinely in the clinic, and is gradually replacing classic cytogenetic methods in some centres. Most of the clinically available array-CGH platforms are designed to detect aneuploidies, well-characterized microdeletions or microduplications and subtelomeric or other unbalanced chromosomal rearrangements. In addition, array-CGH covers numerous CNVs of unclear importance that are scattered throughout the human genome, some of which might be relevant to the DSD (especially if they contain candidate genes or occur de novo). However, this technology is not able to identify balanced chromosomal rearrangements such as translocations and inversions. In addition, some ploidies 19 and low-level mosaicism (affecting <10% of cells that are analysed) might not be detected with array-CGH (Table 1) . Furthermore, the data must be validated using other techniques such as FISH, multiplex ligation-dependent probe amplification or a quantitative CNV assay. 19 Nevertheless, customized Next-generation sequencing In the past 4 years, next-generation sequencing (NGS) technologies have revolutionized the identification of disease-causing genes. These sequencing methods use massive parallel approaches to sequence multiple samples simultaneously. 21 NGS is a simple DNA variant test that can detect single base-pair substitutions, as well as small insertions and deletions involving a few nucleotides. If the patient's phenotype is more consistent with a chromosome abnormality than a simple genetic change, a test to determine karyotype and/or array-CGH are more appropriate initial tests than NGS. However, the latest algorithms are improving the detection of CNVs from high-throughput sequencing approaches. In addition, if a specific diagnosis is suggested from biochemical or hormonal data, then a more focused candidate gene approach is more appropriate initially.
Some studies have claimed that NGS can identify variants with an accuracy of 98.0-99.9% at a depth of 60-90-fold. 22 However, difficulties remain in terms of the quality and efficiency of capture methods and coverage, data transfer, storage and especially bioinformatic analysis. Strategies to interpret allelic variants of unknown importance should be developed, as currently the importance of many findings is unclear. Multiple sources of error, including sequencing errors, incorrect alignment (mismapping) and random sampling, can occur in NGS, especially when read depth is low. 21 In general, NGS cannot identify variations larger than a few base pairs in size, such as insertions and deletions, trinucleotide repeats and some CNVs. 23 Confirmatory Sanger sequencing, multiplex ligation-dependent probe amplification or array-based tests are still necessary to confirm the results of NGS if they are to be used clinically, which increases the cost and time required to reach a diagnosis. [24] [25] [26] The three most common applications of NGS are targeted arrays, whole-exome sequencing and wholegenome sequencing. Targeted arrays are designed to capture panels of known genes involved in conditions such as DSDs, so that these genes can be sequenced at the same time and for a fairly low cost. This approach might be useful when mutations in many different genes, some of which are quite large (such as MAP3K1), can produce the same phenotype (such as testicular dysgenesis). Sanger sequencing of these genes on a oneby-one basis would be laborious and costly in terms of manpower. The development of targeted arrays linked to NGS might be a solution for sc reening of potentially disruptive changes (Table 1) . Whole-exome sequencing is generally more expensive and laborious than targeted strategies; however, the cost of this approach is falling and the clinical application is increasing in some settings. 21, [27] [28] [29] Whole-genome sequencing is being used in some research settings but is currently more costly than whole-exome sequencing. Some of the major challenges with these approaches are the high number of variants detected and incidental or 'bystander' information that is discovered in genes that are not relevant to the DSD but which could have health-related consequences. For example, whole-exome sequencing typically generates 15,000-20,000 variants within the coding region and whole-genome sequencing typically generates 3-4 million variants that differ from the human reference genome. 26 The vast majority of these variants are not related to a particular disease, and only 1-2% are associated with a potential phenotype. 25, 30 Several filters should be used for the selection of deleterious variants: variants with low allelic frequency (<1-5%) in a reference population, synonymous and noncoding variants are generally excluded. Nonsense mutations, frameshift mutations, insertions and deletions and canonical splice site variants are more likely to be deleterious than missense changes, especially if a review of the literature supports the variants' pathogenicity. Indeed, incidental findings of potentially deleterious variants have been reported in normal populations (occurring at a frequency of 3.4% in people of European descent and 1.2% in those of African descent). 31 Thus, clear structures need to be in place to ensure variants are verified by a clinically approved test, to determine what information an individual might want to be told and to provide the support of genetic counselling. 31 As the cost of wholeexome sequencing continues to drop, it could become a frontline test in some centres, being used for the initial analysis of genes related to DSDs. 32 Another challenge in the diagnosis of DSDs is that some occur de novo or even in dominantly inherited forms. As affected individuals are unable to reproduce, large families with affected and unaffected individuals are often not available. The use of family trios (parents and affected child) is very important to facilitate the variant-filtering process, 26 especially for detecting de novo changes. The potential relevance of findings in novel genes is strengthened when changes in the same gene are found in multiple independent families or individuals with DSDs and not in large control databases of ancestrally matched populations. International research collaborations might be needed to achieve this goal. 33 
Prenatal diagnosis of DSDs
Prenatal detection of ambiguous genitalia or genotypephenotype discordance has increased over time because of the widespread use of advanced technical imaging and molecular approaches to determine fetal genetic sex. 34 A prenatal karyotype-phenotype discrepancy has been reported to occur in as many as ~1:2,500 pregnancies. 35 Ambiguous genitalia should be suspected when typical male or female genitalia are not visualized on prenatal ultrasonography performed by an experienced sonographer after 13 weeks of gestation. 36 Several approaches have been developed over the years to determine fetal karyotype, the most recognised of which is the karyotyping of cells cultured from chorionic villi or amniotic fluid (amniocentesis) at ~11-14 weeks of gestation or 16 weeks of gestation, respectively. However, both of these pro cedures have small, but measurable, rates of pregnancy loss, varying from 0.5% to 2.0%. 37, 38 Amniocentesis can only be performed in the second trimester and, although ch orionic villi sampling provides reliable results in the first trimester, its use before the eleventh week of g estation is associated with limb defects. 36 The identification of circulating cell-free fetal DNA (cffDNA) in maternal blood in 1997 provided an important alternative approach for noninvasive prenatal diagnosis. 36, 39 Currently, PCR amplification of cffDNA is the gold standard method to define fetal sex early in pregnancy without any risk of spontaneous abortion. 40 The sensitivity and specificity of fetal sexing using cffDNA can be influenced by the methodology used, the sample types and the gestational age. Different Y chromosome markers (such as SRY and DYS14 [located within TSPY1]) have been used to detect the presence of a Y chromosome. 41, 42 However, two meta-analyses published in the past 5 years did not observe discernible differences between the two markers, with the methodology used and gestational age at sample collection being the main factors that influenced the diagnostic accuracy of sex determination using cffDNA. 40, 41 Using cffDNA, fetal sex can only be determined with an accuracy close to 100% after the eighth week of gestation. 36, 40, 41, 43 However, the earliest gestational age associated with the highest sensitivity and specificity is still being debated. In a meta-analysis published in 2011, which included 10,587 cffDNA tests, sensitivity and specificity at 5 weeks of gestation were 93% and 95%, respectively. 41 To avoid false-negative results, before reporting a test result as female (negative for a Y chromosome), all negative tests collected before the eighth week of gestation should be repeated in the following weeks. 44 In the past few years, cffDNA analysis using NGS has been reported for the diagnosis of some monogenic or X-linked genetic disorders, such as achondroplasia, cystic fibrosis and CAH, but its use in clinical practice is still limited. 41, 45 Sex chromosome DSDs DSDs due to chromosomal abnormalities include Turner syndrome (45,X), Klinefelter syndrome (47,XXY), 45,X/46,XY mosaicism (also known as mixed gonadal dysgenesis) and 46,XX/46,XY chimerism. Despite the fact that most children with a 45,X/46,XY karyotype have a normal male phenotype at birth, 3 the phenotype can be highly variable and it is still one of the most prevalent conditions that presents with atypical genitalia after birth. The most common feature in this group of children is asymmetric development of the gonads, often with a dysgenetic testis on one side and a streak gonad on the other. 46, 47 The karyotype is 45,X/46,XY or its variants with a 45,X cell line and one or more lineages with a normal or structurally abnormal Y chromosome. 45,X/46,XY mosaicism is also associated with short stature, as well as cardiovascular and renal anomalies, but different phenotypes can occur as the result of the presence of Y chromosome deletions, ring chromosomes and isochromosomes. Surveillance for features associated with Turner syndrome is recommended in patients with 45,X/46,XY mosaicism.
Detection of an abnormal Y chromosome in routine analysis depends on the position and the size of the missing Y chromosome segment. Classic cytogenetic analysis can be supplemented with FISH techniques to improve the characterization of chromosomal abnormalities. FISH can be useful for identifying the nature and origin of unknown markers and chromosomal rearrange ments, which might have important implications in sex determination and in the development of gonadal tumours. 48 Array-CGH is an alternative approach to sex chromosomal complement analysis. 49 SNP array analysis can have advantages over classic karyotyping for the identification of cryptic Y chromosome material in patients with Turner syndrome. 50 However, karyotyping retains an important advantage over arrays for the identification of complex mosaicisms, including translocations and rare X chromosome structural variants. SNP genotyping is unable to detect fully balanced X-autosome translocations, and whether low-level mosaicism will be missed with this technique is currently unclear. 49, 50 Mutational analysis using NGS might also be relevant in patients with a DSD related to sex chromosome mosaicism. 51 
46,XY DSDs
46,XY DSDs can present with a large phenotypic spectrum of features. When biochemical data or the presence of associated features indicates that a specific single gene is the cause, traditional approaches to sequencing are usually informative. However, in many cases of testicular dysgenesis or the broad group of 'partial androgen insensitivity' , it is much more difficult to reach a speci fic diagnosis using routine techniques; new molecular tools might help in the investigation of these patients (Figure 1) . Occasionally, specific genetic investigations have been performed using fetal DNA to investigate a known molecular defect in families with a previously affected child. [52] [53] [54] [55] Defining the molecular basis of some forms of 46,XY DSDs can have important clinical implications ( Table 2) .
Abnormal gonadal determination
Abnormalities in the expression of genes involved in the process of gonadal determination can disrupt testicular development. Complete and partial forms of 46,XY gonadal dysgenesis result from complete or partial failure of this process, respectively. Individuals with 46,XY who have complete gonadal dysgenesis usually present in adolescence with absent puberty, typical female internal and external genitalia and streak gonads. In contrast, partial testicular dysgenesis usually presents at birth with ambigu ous genitalia-variable internal and external genitalia are seen. 56 Mutations in SRY and NR5A1 (which encodes steroidogenic factor 1) are the most frequent molecular causes of isolated 46,XY gonadal dysgenesis and variations in MAP3K1 have also been identified in the past few years. 57 Gonadal dysgenesis might be isolated or could be part of a syndrome. When additional features are found, a candidate gene approach is generally successful (for example, WT1 in Denys-Drash syndrome, GATA4 in heart defects or SOX9 in campomelic dysplasia). [58] [59] [60] Human sex development is sensitive to gene dosage effects; duplication and deletion events contribute to anomalies in gonadal development. Abnormal CNVs or expression of several genes involved in testis determination have been identified in patients with 46,XY gonadal dysgenesis.
14 Commercial genetic tests to identify CNVs for SRY, SOX9, NR0B1, DMRT1, NR5A1, WNT4 and WT1, as well as sequencing of each candidate gene are available for use in the clinic. Investigation of gene dosage imbalances using multiplex ligation-dependent probe amplification analysis has provided a good complement to DNA sequencing in patients with 46,XY gonadal dysgenesis, enabling screening for deletions and duplications of several genes simultaneously. 14, 18, 61 The evaluation of the entire genome by array-CGH to identify submicroscopic genomic imbalances on a genome-wide scale, or whole-exome sequencing or wholegenome sequencing, might enable molecular diagnosis of known genes and novel candidate genes for 46,XY gonadal dysgenesis. [16] [17] [18] For example, studies using array-CGH resulted in the identification of known or potentially causative aberrations in some patients with dysgenetic DSDs. 18, 20, 62 One such report analysed copy number variation in 23 individuals with gonadal dysgenesis without a genetic aetiology. Three copy number changes that might cause gonadal dysgenesis were found: a large duplication on the X chromosome that included NR0B1, a rearrangement that seems to affect the region containing SOX9 and a small deletion immediately downstream of GATA4. The deletion close to GATA4 suggests that rearrangements of noncoding sequences that alter gene regulation might account for a proportion of DSDs cases. 20 In another study, a customized 1 million probe array-CGH platform with whole-genome coverage and probe enrichment targeting 78 genes involved in sex development was used to analyse nine patients with 46,XY gonadal DSDs. Three novel candidate regions for 46,XY gonadal dys genesis were identified in two patients: an interstitial duplication of the SUPT3H gene and a deletion of C2orf80. A large duplication encompassing PIP5K1B, PRKACG and FAM189A2 was also detected, but functional analyses of these genes are not available. 18 Many studies of whole-exome sequencing in patients with 46,XY DSDs as a result of gonadal dysgenesis are cur rently underway but, to date, published results are limited. In a pilot study of 10 patients with DSDs that used whole-exome sequencing, a molecular cause was confirmed in five individuals with a previous known genetic diagnosis and potentially in two of five patients in whom no molecular diagnosis could be obtained by current diagnostic approaches. 63 Another report used whole-exome sequencing to describe the first missense mutations in the coding sequence of ZFPM2 associated with 46,XY DSDs in humans. 64 The first loss-of-function mutation in HHAT was also found in a child with testicular dysgenesis and chondrodysplasia attributable to disrupted Hedgehog palmitoylation and signalling. 65 Whole-exome sequencing has also identified disruption of genes known to be associated with gonad development, such as NR5A1. 66 In a report published in 2014, the underlying genetic aetiology of patients with 46,XY DSDs but without a previous genetic diagnosis was investigated by whole-exome sequencing followed by analysis of all known genes associated with DSDs. The identification of the genetic diagnosis was possible in more than a third of patients. 32 Further reports of novel causes of DSDs will probably emerge in the near future.
Abnormal production of testosterone Most cases of 46,XY DSDs that result from enzymatic defects in adrenal and/or gonadal steroid synthesis have a hormonal profile in basal and/or stimulated conditions (after adrenocorticotropic hormone or human chorionic gonadotropin stimulation tests) that indicates the causative defect of the disorder (for example, 3-β hydroxysteroid dehydrogenase deficiency [HSD] type 2, 17α-hydroxylase deficiency or 17-βHSD3; Figure 1 ). The hormonal diagnosis is based on the accumulation of steroid precursors upstream of the enzymatic defect and, frequently, the molecular defect can be identified by Sanger sequencing. 67 In two children with atypical genitalia due to deficiency of the 17β-HSD3 enzyme and a normal Δ4-androstenedione to testosterone ratio after human chorionic gonadotropin stimulation, Sanger sequencing revealed mutations in the HSD17B3 gene, which confirmed the diagnosis of 17β-HSD3 deficiency. 68 Therefore, molecular genetic analysis provides more accurate diagnosis of 17β-HSD3 defi ciency than the serum Δ4-androstenedione to te stosterone ratio. The candidate gene approach is usually the first step in defects of testosterone production and defects of androgen action or metabolism. Human sex development is sensitive to gene dosage effects and duplication and deletion events can be ruled out in gonadal dysgenesis, as well as obvious single gene conditions attributable to associated syndromes. Considering the low frequency of diagnosis using a candidate gene approach, array-CGH and NGS should be the first step of molecular investigation in isolated gonadal dysgenesis as well as in undetermined DSDs, unless associated features are present. Targeted array-based approaches, as well as whole-exome sequencing or whole-genome sequencing might enable a molecular diagnosis to be reached involving known genes and novel candidate genes for 46,XY DSDs. '?' indicates there is no established candidate gene in humans. Abbreviations: 5α-RD2, 5α-reductase type 2; array-CGH, array comparative genomic hybridization; DSDs, disorders of sex development; MLPA, multiplex ligation-dependent probe amplification; NGS, next-generation sequencing.
Androgen insensitivity
Androgen insensitivity syndrome is the most frequently recognized 46,XY DSD and has an X-linked pattern of inheritance. Girls with complete androgen insensitivity syndrome (CAIS) present with a characteristic pheno type (breast development, primary amenorrhoea and scarce pubic hair) and hormonal profile during and after puberty. The CAIS phenotype and the phenotypes of 46,XY DSDs caused by mutations in the LHCGR, NR5A1, CYP17A1 or HSD17B3 genes overlap before the onset of puberty. 69 Using sequencing to identify defects in these genes might establish the diagnosis and avoid the need for a human chorionic gonadotropin stimulation test. By contrast, the phenotype of partial androgen insensitivity syndrome (PAIS) is quite variable, and the clinical presentation depends on the degree of responsiveness of the external genitalia to androgens. Ambiguous genitalia with microphallus, severe hypospadias, a bifid scrotum and palpable gonads is the most frequent phenotype of PAIS. 70 The broad spectrum of phenotypes in patients with PAIS can cause misdiagnosis, as several 46,XY DSDs are attributable to defects in androgen production and can present as PAIS. 71 A diagnosis of PAIS is established unequivocally by the identification of a molecular defect in the AR gene (encodes the androgen receptor).
Mutations in AR are identified in almost all patients with CAIS and in many patients with PAIS. 72, 73 In our experience, Sanger sequencing identifies AR mutations in 89% and 77% of families with CAIS and PAIS, respectively. 72 These patients go through puberty and exhibit the typical phenotype of androgen insensitivity syndrome (gynaecomastia, high basal levels of luteinizing hormone and testosterone, affected brothers or an X-linked pattern of inheritance). However, other reports 74 have indicated that the prevalence of AR mutations in individuals with a PAIS-like phenotype is considerably lower than what we have observed. 72 Identifying the specific AR mutation might not indicate the potential androgen responsiveness in puberty because the phenotype depends on the residual mutant AR function, which can be influenced by different factors, such as co-regulatory proteins. 75 A NGS approach might enable the identification of genetic modifiers; however, these studies would be difficult to interpret conclusively, unless large kindred are available. 
5α-reductase type 2 deficiency
The biochemical diagnosis of a 46,XY DSD caused by 5α-reductase type 2 (5α-RD2; also known as 3-oxo-5α-steroid 4-dehydrogenase 2) deficiency is based on a raised serum testosterone to dihydrotestosterone ratio. To determine the testosterone to dihydrotestosterone ratio correctly, dihydrotestosterone should be measured using a very specific assay, as commercial immuno assays show high cross-reactivity with testosterone. 76 The analytical performance of dihydrotestosterone assays has improved with the use of technology based on liquid ch romatography-mass spectrometry, but this methodology is not available in most laboratories. 77 To accurately analyse this ratio, levels of testosterone should be within the range usually seen after puberty. Therefore, in patients who have not undergone puberty, it is necessary 
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to increase testosterone levels using human chorionic gonado tropin stimulation or injection of exogenous testosterone enanthate. 78, 79 However, especially in neonates, a normal testosterone to dihydrotestosterone ratio does not exclude 5α-RD2 deficiency because transcription of the isoenzyme 5α-RD1, normally not detected before puberty, can occur, thereby partly bypassing the enzymatic block and reducing the reliability of the ratio for diagnosis. 80, 81 Considering the high prevalence of normal testosterone to dihydrotestosterone ratios in affected patients, mutational analysis of the SRD5A2 gene (encodes 5α-RD2) is indicated as the first approach for diagnosis, especially in neonates. 82, 83 This step is clinically important as the diagnosis of a mutation in SRD5A2 in neonates with ambiguous genitalia might influence the choice of sex-of-rearing, as 5α-RD2 deficiency is associated with a change to male social sex. 79, 84 Moreover, many adults with 5α-RD2 deficiency reared as male report a better quality of life than adults reared as female. 85, 86 In addition, male patients can occasionally have children using assisted reproductive techniques, whereas those raised as female usually undergo gonadectomy. 87 
46,XY DSDs of unknown aetiology
Despite advances in our knowledge of the genetic basis of sex development, an aetiologic diagnosis is not possible for a considerable number of people with 46,XY DSDs. 24 In these patients, chromosomal abnormalities are not identified by classic cytogenetic techniques and the hormonal profile is not suggestive of the causative disorder. NGS techniques could enable the identification of novel or unsuspected known genes associated with DSDs in patients for whom a target gene cannot be identified with classic techniques, especially if multiple family members are affected. Studying family trios will be important, especially for identifying de novo changes, and multicentre and international collaborative approaches might identify multiple variants in the same gene in independent families, which will be especially useful if supported by gene-protein expression data or animal models. However, proving causation might be challenging in some cases, particularly if strong modifier effects are pres ent from other genetic, oligogenic or epigenetic influences, or from environ mental effects. Defining monogenic dis orders might become increasing difficult, especially if changes affect enhancers or regulatory regions some di stance from the gene itself.
46,XX DSDs
CAH due to 21-hydroxylase deficiency The diagnosis of 21-hydroxylase deficiency is essentially based on measurements of adrenal steroids; markedly increased serum levels of 17-hydroxyprogesterone in a neonate with ambiguous genitalia defines the diagnosis of the classic form. However, molecular methodologies for diagnosis can be useful in specific situations, such as in male neonates with normal genitalia and moderately increased 17-hydroxyprogesterone levels, to enable differential diagnosis of classic and nonclassic forms of CAH, with therapeutic implications. [88] [89] [90] One of the most recognized uses of molecular-biology techniques is for the diagnosis and treatment of at-risk pregnancies. For example, administration of dexa methasone to suppress adrenal androgen secretion has been used in tertiary centres for >30 years and has proven effective in reducing genital virilization of female fetuses with CAH. [91] [92] [93] The success of treatment depends on when it is started, which should ideally be no later than the seventh week of gestation (before the period of genital sensitivity to androgen action) and should be maintained until the end of pregnancy in affected fetuses. 92 New approaches for prenatal diagnosis have been developed to avoid all male fetuses and unaffected female fetuses being exposed to dexamethasone. Although fetal sex determination using cffDNA was previously thought to have the highest sensitivity and specificity at 8 weeks of gestation, a representative series of 258 pregnancies at risk of CAH found a sensitivity of 96% for identification of Y chromosomal material at the fourth week of gestation. 94 In the past few years, attempts have been made to determine the CYP21A2 genotype in cffDNA early in pregnancy, to minimize the time of dexamethasone exposure in unaffected female fetuses. 95 NGS of cffDNA in maternal plasma at 5.4 weeks of gestation enabled the diagnosis of affected and unaffected female fetuses by linkage analysis of SNPs flanking the CYP21A2. 95 Despite these advances, prenatal dexamethasone therapy cannot be considered as standard care, as some adverse effects have been observed. Children treated in utero have a birth weight within the normal range, but reduced by ~0.4-0.6 kg, and the long-term implications of this finding remain of concern. 96 In another study, unaffected children treated pre natally with dexamethasone had poorer verbal working memory, rated lower on self-perception of scholastic competence and had increased self-rated social anxiety compared with unaffected children who did not receive dexamethasone. 97 Until the long-term risks can be defined, prenatal treatment with dexamethasone should only be performed in tertiary centres that can follow-up all exposed children for long periods. 98 Fully informed consent from parents is needed.
Other CAH diagnoses
In addition to 21-hydroxylase deficiency, other adrenal enzymatic defects can also present with moderately increased neonatal levels of 17-hydroxyprogesterone, such as 3β-HSD type 2 and P450 oxidoreductase deficiency. These patients are occasionally picked up in 21-hydroxylase deficiency neonatal screening programs. [99] [100] [101] [102] Molecular analysis can be useful as a confirmatory test in these patients. [99] [100] [101] [102] Indeed, in P450 oxidoreductase deficiency, both sexes can present with ambiguous genitalia. In addition, P450 oxidoreductase deficiency can be associated with Antley-Bixler syndrome; however, these clinical manifestations might not be evident at birth and can even be absent. 103 
46,XX testicular DSDs and ovotesticular DSDs
Patients with 46,XX testicular DSDs and male genitalia often have SRY translocations. However, the genetic basis of other forms of 46,XX testicular DSDs (with ambig uous genitalia) or ovotesticular DSDs is less well established. [104] [105] [106] Nevertheless, a common molecular origin for these conditions has been suggested, as families containing patients with these two phenotypes have been identified. 107 To date, genetic aetiologies of ovotesticular DSDs include SRY translocations in a small number of patients, inactivating mutations in single genes (such as RSPO1, with associated palmoplantar hyperkeratosis and a predisposition to squamous cell skin tumours) and disruption of regulatory regions that results in altered expression of genes involved in testis determination (such as SOX9 and SOX3). [108] [109] [110] Prenatal diagnosis of 46,XX testicular DSDs has been reported in isolated cases, in which a discrepancy between the karyotype and genitalia was observed during screening for chromosomal aberrations. 104, 111 FISH analysis of amniotic fluid cells could be useful for identifying SRY, as could PCR amplification of the SRY in fetal DNA samples. 111 Although ovotestes most commonly occur with a 46,XX karyotype, they can occur with 46,XX/46,XY chimerism, or more rarely in an individual with a 46,XY karyotype with disruption of the testis-determining genes. For example, high-resolution array-CGH identified a female patient with a 46,XY ovotesticular DSD with testicular tissue on one side and an ovary containing germ cells on the other who had a deletion of ~35 kb affecting exons 3 and 4 of DMRT1. This report suggests that DMRT1 haploinsufficiency can cause 46,XY gonadal dysgenesis and 46,XY ovotesticular DSDs. 112 
Genetic counselling
Genetic counselling is the process by which parents or at-risk relatives of patients with DSDs are informed of the nature and consequences of the disorder, and the probability of developing it or of passing it on to their offspring. The optimal time to determine the genetic risk is before pregnancy so that prenatal testing can be discussed. 113 Family members at risk of an autosomal recessive or X-linked form of a 46,XY DSD can be tested after the identification of a specific molecular defect in an affected family member. Prenatal genetic testing can show that the fetus is unaffected by the disorder or give parents the opportunity to prepare themselves for the birth of a child who has a genetic condition. 114 Nonetheless, several concerns exist regarding the use of genetic tests, for example, parents can experience stress and anxiety about the results and a specific molecular diagnosis is not always possible, especially in 46,XY DSDs. Furthermore, parents carrying mutations might feel guilty about their child's condition and so psychological support is an important component of genetic counselling.
In addition, genetic tests are generally expensive and can cause discrimination and stigmatization. For these reasons, genetic testing should be requested after an extensive discussion about how the result might be useful for patients, their relatives or for management decisions. 33, 115 A geneticist with experience in DSDs is an invaluable member of the DSDs team.
Conclusions
Over the past few years, methodological advances in the diagnosis of monogenic diseases have not only elucidated the molecular aetiology of several DSDs, but also yielded valuable information on the biological processes of sex development. Although many of these techniques are not yet available for routine diagnosis, they will probably contribute to the diagnosis of DSDs in many patients quickly and inexpensively in the near future. However, careful selection of the genetic test indicated for each condition is still important for good clinical practice. Multidisciplinary approaches that include psychological support are essential to prevent unnecessary stress during this challenging process. respectively). They are also partially supported by grants from 
